What does BCHE stand for?

Substrate leaving group effects in the butyrylcholinesterase catalyzed reactions.

Protexia(R), a recombinant pegylated version of human butyrylcholinesterase (BChE), is being developed as a pre-exposure prophylactic and post-exposure therapy for military and civilian victims of nerve agent attacks.

Polyol-induced activation by excess substrate of the D70G butyrylcholinesterase mutant.

Boosting the amounts of an enzyme called butyrylcholinesterase, normally present in small quantities in blood plasma as detoxifiers, can interdict nerve agents entering the bloodstream, so the nerve agents can't reach their targets.

The following values were evaluated: WBC counts, RBC counts, PCV, hemoglobin, heterophils, lymphocytes, monocytes, eosinophils, prealbumin, albumin, [alpha]-globulin, [beta]-globulin, [gamma]-globulin, total protein, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, creatine kinase, calcium, phosphorus, iron, cholesterol, glucose, triglycerides, uric acid, urea, creatinine, total solids, bile acids, and butyrylcholinesterase.

The butyrylcholinesterase activity in muscle and liver tissues was not significantly inhibited.

As AD progresses, acetylcholinesterase levels fall and butyrylcholinesterase levels increase.

In an earlier study, MMSE scores in patients treated with rivastigmine, an inhibitor of butyrylcholinesterase (BuChE) as well as AChE, appeared to decline more slowly than predicted, over a period of up to 5 years.